Hemangioblastomas of the Central Nervous System in Von Hippel-Lidau Syndrome and Sporadic Disease

祁晋清,袁先厚,郭国炳,陈卫国,江普查
DOI: https://doi.org/10.3969/j.issn.1009-153x.2002.02.003
2002-01-01
Abstract:Objective To explore the clinical manifestations, management and prognosis in the patients with central nervous system (CNS) hemangioblastomas (HB) in von Hippel -lindau syndrome (VHL) and sporadic disease. Methods The data of 66 petients with CNS HB treated in our department were analysed retrospectively. VHL gene mutation and VEGF expression were detected in the patients with CNS HB who were recently treated. Results Of 66 patients with HB, 58 were sporadic and 8 related with VHL. The 79 lesions were observed because there were multiple lesions in 8 patients. Seventy operations were performed in all patients, including 5 patients accepted operations more than one time. Of 70 operations, 64 came to total resection of HB and 6 to part. Of 70 operations, 46 were very good operative outcomes, 18 relatively good and 3 produced no changes in the patients. Three patients died after the operation. Of 57 patients followed up for 0.5-16 years (averagely 6.7 years), 41 returned to work, 7 completly or partly took care of themselves and 9 died. The rate of gene mutation is 75% (187 24); High expression of VEGF were observed in HB. Conclusions The operative treatment outcomes of CNS HB patients are good. However, the management of the patients with HB related to VHL is much more difficult than that of ones with sporadic HB. Differentiating the patients with HB related to VHL from the ones with sporadic HB is necessary for correctly predicting the prognosis. Related molecalar genetics determinetion should be performed if it is available.
What problem does this paper attempt to address?